drugset / Trial / NCT00633932

Reflux Esophagitis Phase III Study (Initial Treatment)

NCT00633932

Phase 3 Completed 602 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by assessment of presence/absence of Reflux Esophagitis at Week 8 according to the Los Angeles classification .

Timeline

Start
2007-12
Primary completion
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg Oral
Subject Esomeprazole Small molecule 40 mg Oral
Subject Omeprazole Other / unclassified 20 mg Oral

Indications